Skip to main content

Konvomep FDA Approval History

Last updated by Judith Stewart, BPharm on Sep 3, 2022.

FDA Approved: Yes (First approved August 30, 2022)
Brand name: Konvomep
Generic name: omeprazole and sodium bicarbonate
Dosage form: Powder for Oral Suspension
Company: Azurity Pharmaceuticals, Inc.
Treatment for: Stomach Ulcer, Gastrointestinal Hemorrhage

Konvomep (omeprazole and sodium bicarbonate) is an oral liquid formulation of the proton pump inhibitor (PPI) omeprazole and sodium bicarbonate combination indicated for the treatment of active benign gastric ulcer, and reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients.

Development timeline for Konvomep

Sep  3, 2022Approval FDA Approves Konvomep (omeprazole and sodium bicarbonate for oral suspension) for Gastric Ulcer and Reduction of Risk of Gastrointestinal Bleeding in Critically Ill Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.